

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 8180)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND CLARIFICATION ON PRESS ARTICLES

This announcement is made at the request of The Stock Exchange of Hong Kong Limited.

The board (“**Board**”) of directors (“**Directors**”) of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) has noted the recent increase in the price and trading volume of the shares of the Company (“**Shares**”). Having made such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that it is not aware of any reasons for such increase in price or trading volume of the Shares or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board has noted there were press articles in Hong Kong today which stated the following events or speculations (as the case may be) in relation to the Group:

- (i) the Group was granted provincial distribution rights (“**Grant of Distribution Rights**”) of two Levocarnitine Injections (左卡尼丁注射液) respectively manufactured by pharmaceutical manufacturers in Italy (“**Italy Levocarnitine Injection**”) and the People’s Republic of China (“**PRC**”) (“**PRC Levocarnitine Injection**”) in Zhejiang province;
- (ii) the Group intends to step into the medical device market of the PRC; and

(iii) the Company is confident in proceeding with the transfer of the listing of Shares from the Growth Enterprise Market (“**GEM**”) to the Main Board of The Stock Exchange of Hong Kong Limited (“**Transfer of Listing**”).

In respect of the Grant of the Distribution Rights, detailed disclosure on the recent development of the Group’s business in the distribution of Italy Levocarnitine Injection and PRC Levocarnitine Injection in the PRC has been made in the first quarterly report of the Group for the three months ended 31 March 2014.

In respect of the speculations set out in (ii) and (iii) above, the Board wishes to clarify that the Company may only consider to proceed with stepping into the medical device market of the PRC or the Transfer of Listing should time and conditions allow and where appropriate opportunity arises and has no concrete plan in respect of the same currently.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By Order of the Board
New Ray Medicine International Holding Limited
Lee Chik Yuet
Executive Director

Hong Kong, 29 May 2014

As at the date of this announcement, the executive Directors are Mr. Zhou Ling, Mr. Dai Haidong, Ms. Yang Fang and Mr. Lee Chik Yuet; and the independent non-executive Directors are Mr. Ho Hau Cheung, BBS, MH, Mr. Sung Hak Keung, Andy and Mr. Leung Chi Kin.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at <http://www.newraymedicine.com>.